TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00007787

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cyclosporine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-human thymocyte globulin (rabbit)
Description: Anti-human thymocyte globulin (rabbit) will be given at a dose of 1.5 mg/kg while undergoing transplantation. Second and subsequent doses of Thymoglobulin® will be administered if, at 24 hours post-anastomosis, the serum creatinine has not decreased by at least 20% from the pre-transplant level. Additional Anti-human thymocyte globulin (rabbit) will be given at a dose of 1.5mg/kg daily for a minimum of 5 days to a maximum of 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Study: NCT01712451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol xinafoate, fluticasone propionate
Description: LIPO-102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol xinafoate, fluticasone propionate
Description: LIPO-102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol xinafoate, fluticasone propionate
Description: LIPO-102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol xinafoate
Description: Salmeterol
Study: NCT03791541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist services
Description: Additional pharmacist/pharmacy student follow-ups, counseling, and other services
Study: NCT05544656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolperisone Hydrochloride
Description: Tolperisone Hydrochloride tablets of 150 mg, administered three times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo administered three times a day
Study: NCT02845011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiovisual compression feedback
Description: The Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) is a handheld device consisting of three components. The rescuer-side has a red palm-sized push-button with a pictogram illustrating proper use. The center unit is composed of a stable plastic base containing an arrangement of springs, and the patient-side consists of liquid-absorbent polyurethane foam. Application of 400 ± 30 Newtons of force results in an audible click alerting the rescuer to cease compression, and an additional click on decompression alerts the rescuer to resume compression.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Manual Chest Compression
Description: Cardiopulmonary resuscitation according to published international guidelines.
Study: NCT00545116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hesperidin
Description: 250 mg of hesperidin twice a day taken oraly in a biscuit or in milk for 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hesperidin
Description: 250 mg of hesperidin twice a day taken oraly in a biscuit or in milk for 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hesperidin
Description: 250 mg of hesperidin twice a day taken oraly in a biscuit or in milk for 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hesperidin
Description: 250 mg of hesperidin twice a day taken oraly in a biscuit or in milk for 6 months
Study: NCT01066130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive individualized psychosocial treatment
Description: Each person was given psychosocial treatment and support by a medical social worker a maximum of one time each week for a period of up to 2 years after inclusion. Treatment was designed by a medical social work on the basis of the individual's personal needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimal treatment arm
Description: Minimal social measures were provided to individuals in this arm. No treatment that included conversational therapy was given.
Study: NCT03427801

Intervention type: DRUG
Intervention: Erythropoiesis-Stimulating Agent
Description: erythropoiesis-stimulating agent: Mircera or Darbepoietin
Study: NCT03559127

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: For the Group A. Applied Cryotherapy at 6 oC
Description: Patients assigned to this group receive a final irrigation with 5 mL cold (6 oC) 17% EDTA followed with 20 mL cold (6 oC) sterile saline solution dispensed to the WL using a cold (6 oC) metallic micro-cannula included in the Endo Vac System (Kerr Endo) for 5 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: For the Group B. Applied Cryotherapy at 2.5 oC
Description: Patients assigned to this group receive a final irrigation with 5 mL cold (2.5 oC) 17% EDTA followed with 20 mL cold (2.5 oC) sterile saline solution dispensed to the WL using a cold (2.5 oC) metallic micro-cannula included in the Endo Vac System for five minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control Group (CG). Applied irrigant at room temperature
Description: Patients assigned to this control group were treated identically to the experimental groups, except that receive a final flush with 5 mL (room temperature) 17% EDTA followed with twenty mL (room temperature) sterile saline solution delivered to the WL using a metallic micro-cannula included in the Endo Vac System for five minutes.
Study: NCT05511441

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery Without Aspirin Withdraw
Description: Routine Minimally Invasive Thoracic Surgery Without Aspirin Withdraw
Study: NCT04712916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education
Description: Individualized education intervention on medication use, appropriate diet and physical activity was explained to participants. Participants were guided on achieving recommended metabolic equivalent per week (MET) physical activity considering their health status and daily activities. Furthermore, participants were guided on appropriate dietary recommendation and resolving non-adherence behaviour to medication(s), diet and physical activity.
Study: NCT02311517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 90 patients are randomly allocated into two groups: ropivacaine group (n=45), saline group (n=40). In the ropivacaine group, ultrasound-guided serratus anterior plane block is performed with 0.4 ml/kg of 0.375% ropivacaine after induction of anesthesia. In the saline group, ultrasound-guided serratus anterior plane block is performed with 0.4 ml/kg saline after induction of anesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study: NCT01195116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 1 mcg/kg/hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 1mcg/kg/hr
Study: NCT04309162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft tissue therapy
Description: Soft tissue therapy consists of various soft tissue manipulating techniques which includes the stroking, percussive and tapping manipulations. The treatment techniques are divided according to the body parts. under this techniques are tapping, flat finger kneading, Stroking, skin rolling etc.
Study: NCT02413424

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: 60 ml of 2mM sucralose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: 60 ml of 2mM sucralose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 60 ml of water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glucose load

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: glucose load

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glucose load
Study: NCT02525276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: The exercise intervention will conduct the following training program 4 days/week for 6 months: endurance training consisting of supervised training on a bike ergometer for 20 min at 70% of maximal heart rate (HR) the first week, increased by 5 min each week until reaching 40 min. Then the intensity will be increased to 80% of max HR over the next month and recalculated every month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: The exercise intervention will conduct the following training program 4 days/week for 6 months: endurance training consisting of supervised training on a bike ergometer for 20 min at 70% of maximal heart rate (HR) the first week, increased by 5 min each week until reaching 40 min. Then the intensity will be increased to 80% of max HR over the next month and recalculated every month.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hormone treatment
Description: Continually estradiol and gestagens - tablets and patches or cyclic estradiol and gestagens - tablets or patches.~Including:~Drospirenon, Norethisteronacetat, Medroxyprogesteronacetat
Study: NCT05413512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute psychological stress
Description: Participants will undergo an acute psychological stress task that has been shown to elicit neural, cardiovascular, and psychological (feelings of stressfulness) responses.
Study: NCT02525276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone treatment
Description: Continually estradiol and gestagens - tablets and patches or cyclic estradiol and gestagens - tablets or patches.~Including:~Drospirenon, Norethisteronacetat, Medroxyprogesteronacetat
Study: NCT05346250

Intervention type: BEHAVIORAL
Intervention: Non-exercise control
Description: 12 month lifestyle education

Intervention type: BEHAVIORAL
Intervention: Moderate intensity exercise
Description: 12 month moderate intensity exercise by brisk walk 30 min per day and more than 5 days per week.

Intervention type: BEHAVIORAL
Intervention: Vigorous intensity exercise
Description: 6 month vigorous intensity exercise on treadmill for 30 min per day and more than 5 days per week, and subsequent 6 month moderate exercise by brisk walk 30 min per day and more than 5 days per week.
Study: NCT04108442

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional
Description: Surgeons (rather than individual subjects) will be randomized to traditional Postoperative follow-up modality groups. They will adhere to this form of postoperative follow-up for all of their surgical patients (subjects) for one month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual
Description: Surgeons (rather than individual subjects) will be randomized to virtual postoperative follow-up modality group. They will adhere to that form of postoperative follow-up for all of their surgical patients (subjects) for one month.
Study: NCT04376879

Intervention type: OTHER
Intervention: Data monitoring for 48h within the first 24 hours of admission for COVID-19
Description: The admission variables and those constituting the predictive score (blood pressure, temperature, oxygenotherapy, biological analysis...) will be collected for 48 hours after enrolment (i.e within the first 24 hours of admission )
Study: NCT00562120

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single oral dose of Placebo is dosed during the study in order to ascertain the effect of placebo on measures and in order to maintain the blind of the other drugs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allegra
Description: A single oral dose of Allegra is dosed to subjects in combination with PF-03654746.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allegra-D
Description: A single oral dose of Allegra-D is dosed to subjects as an active comparator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03654746
Description: A single oral dose of PF-03654746 is the investigational drug being studied.
Study: NCT02698930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Randomly selected patients of the dexmedetomidine group are given intravenous 0.4mcg/kg/h of dexmedetomidine from the beginning of the anesthesia to postoperative 1 day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Group given intravenous 0.4mcg/kg/h of normal saline from the beginning of the anesthesia to postoperative 1 day.
Study: NCT01266603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDIL-2
Description: 720,000 IU/kg by vein over an approximate 15 minute period every eight hours, for a maximum of 14 doses per cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recMAGE-A3 + AS15
Description: 300 μg plus 420 μg of CpG7909 (a part of the Adjuvant System AS15) by intermuscular injection within 24 hours from first dose of HDIL-2.
Study: NCT04975724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposom Forte
Description: Liposom Forte 28mg/2ml solution for injection contains a mixture of purified hypothalamic phospholipids (PLs) from swine brains. The key components of the phospholipid mixture are phosphatidylcholine (PC), phosphatidylethanolamine (PE) and phosphatidylserine (PS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: The medicinal product Citalopram Aurobindo contains citalopram as active ingredient available on the market in 20 mg film coated tablets. The tablets are divisible in two equal part of 10 mg as reported in the SmPC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: The medicinal product Citalopram Aurobindo contains citalopram as active ingredient available on the market in 20 mg film coated tablets. The tablets are divisible in two equal part of 10 mg as reported in the SmPC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Liposom Forte Placebo (2 ampoules of 2 ml solution for injection)
Study: NCT01207492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Taken orally twice daily
Study: NCT00198354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine + cisplatine
Description: gemcitabine 1250 mg/m², D1+D8 cisplatine 80 mg/m², D1 (D1=D22)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine + cisplatine
Description: gemcitabine 1250 mg/m², D1+D8 cisplatine 80 mg/m², D1 (D1=D22)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Carboplatine
Description: paclitaxel 200 mg/m², D1 carboplatin AUC 6, D1 (D1=D22)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Carboplatine
Description: paclitaxel 200 mg/m², D1 carboplatin AUC 6, D1 (D1=D22)
Study: NCT04650750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiao-Feng-San+Shian-Fang-Hwa-Ming-Yiin
Description: Xiao-Feng-San is a common Chinese herbal preparation, composed of 13 herbs, which is used to treat patients with dermatitis. The component of Xiao-Feng-San has immunomodulatory activity. Shian Fang Hwa Ming Yiin is another common Chinese herbal preparation, composed of 12 herbs, which is used to treat patients with carbuncles and acne. The component of Shian Fang Hwa Ming Yiin has anti-inflammation and anti-microbial effect.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar placebo 4g twice a day for two months
Study: NCT01500616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: type = exact number, unit = mg, number = 750, form = tablet, route = oral use, every 8 hours for 12 weeks in combination with pegylated interferon alfa (Peg-IFN alfa) and ribavirin (RBV) during 48 weeks for eligible non treated HIV patients and for patients whose highly active antiretroviral therapy (HAART) regimen is the combination of ritonavir-boosted atazanavir, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or the combination of raltegravir, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or etravirine, TDF, plus either emtricitabine or lamivudine, or etravirine, abacavir, plus either emtricitabine or lamivudine, or rilpivirine, TDF, plus either emtricitabine or lamivudine, or rilpivirine, abacavir, plus either emtricitabine or lamivudine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: type = exact number, unit = mg, number = 1125, form = tablet, route = oral use, every 8 hours for 12 weeks in combination with Peg-IFN alfa and RBV during 48 weeks when patient's HAART regimen is the combination of efavirenz, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or etravirine, TDF, plus either emtricitabine or lamivudine, or etravirine, abacavir, plus either emtricitabine or lamivudine, or rilpivirine, TDF, plus either emtricitabine or lamivudine, or rilpivirine, abacavir, plus either emtricitabine or lamivudine.
Study: NCT01040273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01337596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2951742
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2951742
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2951742
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2951742
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2951742
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2951742
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2951742
Description: Administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously
Study: NCT04646694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: The use of oral Ketamine in this study is experimental.This study will look at how effective and safe Ketamine.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo is given in this study to reduce the chances of believing that pain after surgery is getting better because one is receiving oral Ketamine
Study: NCT03012893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound sagittal scan
Description: Convex transducer will be placed at patient's neck using paramedian sagittal scan and pointing toward the chest apex aiming to identify the first rib. Then move the transducer medially to identify the transverse process along with identify C7 transverse process will appear on the image as a hyperechoic shadow without continue to the rib laterally. Place the C7 spinous process on the midpoint of the probe and the spinous process correspondence to the midline will be marked as C7.
Study: NCT03866031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: implant-supported mandibular overdenture
Description: The implant-supported overdentures will be placed in immediate functional loading on the same day of implants placement. A direct restorative protocol will be applied to modify the existing prosthesis to implant-supported overdentures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: implant-supported mandibular overdenture
Description: The implant-supported overdentures will be placed in immediate functional loading on the same day of implants placement. A direct restorative protocol will be applied to modify the existing prosthesis to implant-supported overdentures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: implant-supported mandibular overdenture
Description: The implant-supported overdentures will be placed in immediate functional loading on the same day of implants placement. A direct restorative protocol will be applied to modify the existing prosthesis to implant-supported overdentures.
Study: NCT02437513

Intervention type: DEVICE
Intervention: NewBreez
Description: Intralaryngeal prosthesis to protect the airways
Study: NCT05201742

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: Threshold inspiratory muscle training was performed for 6 weeks with device.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incentive Spirometry
Description: Incentive spirometry was performed for 6 weeks with device.
Study: NCT04375969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body cryostimulation treatment
Description: The WBC is apporved by National Ministry of Health. It uses cryochamber with low temperature -110 oC. The patient, minimally dressed (e.g., bathing suit, socks, clogs, headband, and surgical mask), remains 30sec at -60°C (vestibule) for body adaptation and, then, passes to the cryochamber, at -110°C and stay there 3 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connection WBC treatment and HIIT training
Description: WBC combination with Exercise HIIT according to Litlle protocol from 2011. This exercise protocol will be applied together with cryo-sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: This group willnot to change their daily habits . The measurements will be taken at baseline and at the end of the study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT training group
Description: This group will do the training program without cold exposure
Study: NCT04138069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLB+Aerobic Bicycling
Description: Combination of Breathing control and Purse lips breathing technique for 5 minutes at the start of session.~Purse lips breathing with aerobic bicycling for 8 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Bicycling
Description: Breathing control for 5 minutes at the start of session.~Aerobic bicycling for 8 minutes
Study: NCT04484948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scleroderma health assessment questionnaire (SHAQ), BHT, and 6MWT
Description: 1. Participants will perform the SHAQ.~2. BHT and 6MWT will be performed in the randomized way for each participant.~3. For BHT, the participants will be told to sit comfortably on a chair, and breath normally. After 1 minute, they were required to make a maximum expiration followed by a maximum inspiration and to hold the breath as long as possible at maximum inspiratory level. This procedure was repeated three times, with 5-minute intervals between the tests.~4. 6MWT will be performed according to the ATS guidelines.~5. Information on CXR, TTE, and PFT (FVC%, DLCO%) will be obtained from the medical record if the data was obtained within 3 months. If not, the tests will be performed.~6. BHT and PFT will be followed by six months after the first breath-holding test to confirm the responsiveness.~7. Additional 30 patients with systemic sclerosis will be collected to perform the test-retest reliability of BHT.